#67 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
This article discusses a high-dose CBD gummy product containing 900mg of CBD along with trace amounts of other cannabinoids, terpenes, and less than 0.3% THC. The study evaluates the quality, evidence, and real-world effectiveness of these Pharma CBD Gummies, which could potentially offer a practical solution for patients seeking high-dose CBD options for daily use. The practical takeaway for clinicians is that this product may provide an alternative for managing symptoms in patients requiring higher doses of CBD, but it’s essential to consider the potential interactions with other medications and individual patient responses when prescribing or recommending such products.
🔬 In the realm of cannabis-based therapies, a growing interest lies in high-dose CBD gummies, such as those containing 900mg of full spectrum CBD. These products often include trace amounts of other cannabinoids, terpenes, and less than 0.3% THC. (Schoenhard et al., 2021) While the evidence supporting high-dose CBD for daily use is still evolving, it’s crucial to acknowledge potential confounders like individual patient responses, interactions with other medications, and the quality of the product itself. (Bonn-Miller et al., 2017) In clinical practice, healthcare providers should consider these high-dose CBD options as a potential addition to treatment plans for patients seeking alternative therapies, but should emphasize the importance of individualized dosing, regular monitoring, and ongoing evaluation of efficacy and safety. (
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
